PF-06412562
Pharmaceutical compound
From Wikipedia, the free encyclopedia
PF-06412562, also known as CVL-562, is a moderately potent and highly selective dopamine D1 and D5 receptor partial agonist which is under development for the treatment of the cognitive symptoms of schizophrenia.[1][2][3][4] It is taken orally.[1] The drug has been reported to produce pro-motivational effects in humans.[3][5] PF-06412562 is under development by Pfizer and Cerevel Therapeutics.[1][2] As of August 2025, it is in phase 1/2 clinical trials.[1][2] The drug was also under development for the treatment of Parkinson's disease and cognition disorders, but development for these indications was discontinued.[1][2] Its development for Parkinson's disease was discontinued for business reasons unrelated to safety in 2017.[6]
| |
| Clinical data | |
|---|---|
| Other names | PF06412562; PF-6412562; PF6412562; CVL-562; CVL562 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine D1 and D5 receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H17N5O |
| Molar mass | 331.379 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Chemistry
Synthesis
The chemical synthesis was described (Ex 6):[7]
Protection of 4-Chloro-1H-pyrazolo[4,3-c]pyridine [871836-51-0] (1) with 2,3-Dihydropyran [110-87-2] (2) gives 4-chloro-1-(oxan-2-yl)-1H-pyrazolo[4,3-c]pyridine [1416713-66-0] (3). Suzuki reaction between 4-Methoxy-2-methylphenylboronic acid pinacol ester [214360-68-6] (4) and 5-Bromo-4,6-dimethylpyrimidine [157335-97-2] (5) gives 5-(4-methoxy-2-methylphenyl)-4,6-dimethylpyrimidine [1609259-54-2] (6). Demethylation of the ether gives rise to 4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenol [1609259-55-3] (7). Reaction of this with 3 gives 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1-(oxan-2-yl)pyrazolo[4,5-c]pyridine, PC90116929 (8). Tetramethyl‑di‑tBuXPhos [857356-94-6] is a bulky, electron‑rich biaryl monophosphine ligand used in palladium‑catalysed cross‑coupling reactions. Deprotection of the THP protecting group in acid completed the synthesis of PF2562 (9).
